AD	Autoimmune Disease
ANA	Antinuclear Antibody
CR	Complete Response
CTLA-4	Cytotoxic T-Lymphocyte-Associated Protein 4
DCR	Disease Control Rate
DLT	Dose-Limiting Toxicity
EMT	Epithelial–Mesenchymal Transition
ICIs	Immune Checkpoint Inhibitors
irAEs	Immune-related Adverse Events
mOS	Median Overall Survival
mPFS	Median Progression-Free Survival
MSI	Microsatellite Instability
MSS	Microsatellite Stable
MPR	Major Pathologic Response
NPR	Non-Progression Rate
ORR	Objective Response Rate
PD-1	Programmed Cell Death Protein 1
PD-L1	Programmed Cell Death Protein Ligand 1
PFS	Progression-Free Survival
PR	Partial Response
TC	Thymic Carcinoma
TET	Thymic Epithelial Tumor
TILs	Tumor-Infiltrating Lymphocytes
TMB	Tumor Mutational Burden
VEGFR	Vascular Endothelial Growth Factor Receptor